Ascendis Pharma (ASND) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ASND's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Ascendis Pharma A/S (ASND) Jefferies Global Healthcare Conference 2026 November 17, 2026 6:30 AM EST Company Participants Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, …

Ascendis Pharma A/S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched achondroplasia drug YUVIWEL…

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript…

Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing …

COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesd…

– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products (COM…

COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12, 20…

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with …

COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted …

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026…

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They presently have a…

Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and …

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback.…

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company's ordinary…

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and c…

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the streng…

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment…

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare C…

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress …

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.…

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.…

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutica…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

